CAS 1434048-34-6

2-[1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4'-bipyridin]-2'-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one

CAS : 1434048-34-6

Formule : C₃₇H₄₄N₈O₄

Degré de pureté : %

Couleur et forme : Solid

Masse moléculaire : 664.7965

Ref: IN-DA009CMK

Fenebrutinib

CAS : 1434048-34-6

Fenebrutinib

Degré de pureté : ≥98%

Masse moléculaire : 664.8g/mol

Ref: 54-BUP04653

Fenebrutinib

CAS : 1434048-34-6

Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).

Formule : C₃₇H₄₄N₈O₄

Degré de pureté : 98.26% - 98.94%

Couleur et forme : Solid

Masse moléculaire : 664.8

Ref: TM-TQ0242

Fenebrutinib (GDC-0853)

CAS : 1434048-34-6

Fenebrutinib is a long-acting monoclonal antibody that inhibits the activity of stem cell factor. It binds to the stem cell factor, preventing it from binding to its receptor and causing platelets to aggregate. Fenebrutinib has been shown to be safe and effective in preclinical studies for heparin-induced thrombocytopenia and related conditions, including autoimmune diseases such as rheumatoid arthritis. Fenebrutinib is being developed as a treatment for cancer, inflammatory bowel disease, and other autoimmune disorders. This drug is selective for c-KIT (a type of enzyme called kinase) but does not affect other kinases such as JAK1 or JAK2.

Formule : C₃₇H₄₄N₈O₄

Degré de pureté : Min. 95%

Masse moléculaire : 664.8 g/mol

Ref: 3D-JHC04834